GlassScriptPhysician profile
Stacey M Schulte
NPI 1194155861
$5,307.32
in general payments reported to CMS, 2019-2025
15 companies · $3,770 in 2025
The $3,770 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $116 · 2024: $1,309 · 2025: $3,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,648 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Travel and Lodging: $47.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,648.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Travel and Lodging | $47.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,696.65 | 2023-2025 | |
| Lundbeck LLC | $234.99 | 2023-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $233.14 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $186.44 | 2024-2025 | Qelbree |
| Corium, LLC | $181.02 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $175.97 | 2022-2025 | Rexulti |
| Tris Pharma INC | $111.95 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.38 | 2024 | Caplyta |
| Harmony Biosciences LLC | $82.27 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $82.23 | 2024-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $62.72 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $56.30 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $54.04 | 2025 | Spravato |
| Noven Therapeutics, LLC | $40.96 | 2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $20.26 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Schulte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.